21st Century Cures Act Is an Easy Pill to Swallow
- Dec 21, 2016
Legislation Could Be a Boon to Biotech
Who said the government’s always divided? By a largely bipartisan vote, the House (392 to 26) and the Senate (94-5) approved the $6.3 billion 21st Century Cures Act to fund various health and life science initiatives. President Obama signed the bill into law days after it left the Senate. The funds will be divided among various programs and agencies.
The Nation Institutes of Health (NIH) will receive $4.8 billion over the next 10 years to research cures for a variety of diseases; $1.8 billion of which will go to preventing, detecting and curing cancer. Funds will also be allocated to a precision medicine initiative that “customizes” drugs based on a patient’s lifestyle and genetic makeup.
The Food and Drug Administration will receive $500 million over the next decade to add research staff and help streamline and quicken the approval process for drugs and medical devices. One such method will entail making it easier for previously authorized drugs to be used for other diseases, also known as off-labeling; another is giving the FDA more leeway in the use of stem cells.
States will receive $1 billion in funding over the next 2 years to tackle mental health issues and the growing problem of opioid addiction. Opioid-related deaths in the U.S. have quadrupled over the past 17 years.
Some legislators and consumer advocacy groups opposed the bill because they feel that standards may weaken oversight of clinical drug trials and medical device manufacturers, thus increasing risk to end-users. They also called into question the safety and efficacy of making it easier to off-label medications.
The 21st Century Cures Act will be funded, in part, by money from the Affordable Care Act.
If you have any questions, we'd like to hear from you.
Explore More Insights
It's Not You, It's Your Software | Embracing the Future as a Digital CFORead More
Proposed Regulations for Determining Proceeds, Basis, and Reporting Requirements for Digital AssetsRead More
Receive the latest business insights, analysis, and perspectives from EisnerAmper professionals.